---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-195400"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:37:18.435857+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Madrigal reports Q2 2024 net sales of $14.6M from Rezdiffra launch; cash $1.1B

## Summary
- Rezdiffra U.S. launch generated $14.6M net sales in Q2 2024; no product sales in prior-year period.
- Coverage in place for >50% of commercial lives; <5% of covered lives require biopsy.
- EMA decision on resmetirom MAA expected mid-2025; plans to directly commercialize in Europe.
- Q2 operating expenses $177.2M vs $86.5M YoY; SG&A drove increase on launch activities.
- Cash, equivalents and marketable securities $1.1B vs $634.1M at Dec 31, 2023.

## SEC filing metadata
- accession: 0001193125-24-195400
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312524195400/0001193125-24-195400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312524195400/d813823d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-195400
- JSON: https://secwatch.observer/filing/0001193125-24-195400.json
- Plain text: https://secwatch.observer/filing/0001193125-24-195400.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.